Physician

Martin Quan Tran, D.O.

According to 2025 Medicare claims, Martin Tran, D.O. (NPI: 1851395891) practices nephrology in the Johnson City, TN market, with the plurality of this provider's patient population coming from Washington, TN. This provider's primary affiliated billing organization is EAST TENNESSEE MEDICAL ASSOCIATES, P.C. (NPI: 1619089034; TIN: 62-1017477) and primary practice location at 37604-6287. Tran is affiliated with the Mission Health Partners, LLC (ACO ID: A2591), participating under the MSSP model.

Tran's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 546 traditional Medicare patients, billed 1,801 HCPCS/CPT codes, and received $183,432 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 3,517 prescription claims across 542 beneficiaries totaling $676,083 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 454 claims. Open Payments data shows 95 records totaling $1,876. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $364,527 to $183,432. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $412,002 and ending at $676,083. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,948 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	650	3,763	$364,527
2016	686	2,541	$190,289
2017	798	2,961	$220,128
2018	814	3,277	$256,251
2019	783	2,911	$235,267
2020	668	2,306	$201,017
2021	611	2,002	$211,114
2022	559	1,898	$185,471
2023	529	1,781	$180,727
2024	546	1,801	$183,432

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	335	3,042	$412,002
2016	414	3,569	$551,894
2017	475	3,995	$693,915
2018	533	3,966	$484,179
2019	536	3,485	$639,766
2020	516	3,237	$628,382
2021	491	3,093	$381,014
2022	481	2,955	$348,342
2023	530	3,232	$478,403
2024	542	3,517	$676,083

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	27	407	$36,551
2016	13	350	$29,532
2017	41	424	$23,319
2018	55	587	$41,963
2019	59	706	$39,886
2020	60	727	$32,984
2021	53	623	$23,234
2022	54	662	$17,069
2023	45	497	$8,268
2024	40	454	$8,653

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	35	118	$262
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	112	123	$131
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	62	62	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	312	684	$85
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	170	638	$59

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	294	12,341	$235,470
Tavneos	Avacopan	11	330	$184,585
Jardiance	Empagliflozin	49	2,700	$51,960
Kerendia	Finerenone	40	1,770	$39,211
Lokelma	Sodium Zirconium Cyclosilicate	42	1,522	$35,704

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7520	Sirolimus, oral, 1 mg	N	N/R	11	$1,875
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	102	$1,741
J7507	Tacrolimus, immediate release, oral, 1 mg	N	13	111	$1,604
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	15	129	$1,510
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	32	$1,238

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$1,876	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Martin Quan Tran, D.O.?

Tedicare shows public-source Medicare data for Martin Quan Tran, D.O. (NPI 1851395891), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Martin Quan Tran, D.O. have ACO affiliation data?

Martin Quan Tran, D.O. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591).

What billing organization is linked to Martin Quan Tran, D.O.?

Martin Quan Tran, D.O. is linked to EAST TENNESSEE MEDICAL ASSOCIATES, P.C. (billing NPI 1619089034) in the available physician profile data.

Does Martin Quan Tran, D.O. have Open Payments data?

Martin Quan Tran, D.O. has 95 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.